Navigation Links
Study on Timing of Spinal Surgery

According to a spine surgeon Alexander Vaccaro, M.D., timing of surgery is crucial in a case of severe spinal injury//. It is a matter of great argument among the orthopaedic surgeons.

Should surgeons operate immediately, within hours of the severe spinal injury, to try to limit the damage to the spinal cord and surrounding tissues, as many surgeons believe? Or won’t it make a difference in how a patient ultimately fares, as others, citing their experiences, say?
Dr. Vaccaro, professor of orthopaedic surgery and neurological surgery at Jefferson Medical College of Thomas Jefferson University in Philadelphia and the Rothman Institute at Thomas Jefferson University Hospital and his colleagues are trying to find a solution for this critical question.

Dr. Vaccaro, in conjunction with Michael G. Fehlings, M.D., at Toronto Western Hospital, is spearheading a multicenter trial called STASCIS, which looks at timing of surgery, the timing of spinal reduction and a prospective evaluation of how patients do.

STASCIS is an acronym for the Surgical Treatment of Acute Spinal Cord Injury Study. Begun in 2003, STASCIS is both an observational and prospective randomized study aimed at determining if patients with spinal cord injury will benefit from early treatment to reduce pressure on the spinal cord.

Two types of injuries occur when the spinal cord is damaged, says Dr. Vaccaro, co-director of the Delaware Valley Regional Spinal Cord Injury Center at Jefferson. The primary injury is the actual physical insult to the spinal cord, including bruising, bleeding and any kind of disruption to the cord and its functioning. But a secondary injury also occurs, usually between the first day after the initial damage to as many as three to five days later. Cell and tissue death begins – including apoptosis, or programmed cell death – as electrolytes like calcium and sodium become out of balance.

This secondary cascade of spinal cord in
'"/>




Page: 1 2 3

Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study Timing Spinal Surgery

(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...zart, could have a therapeutic effect on epilepsy,...448 have been found to decrease epileptic attacks....national research on music therapy, said it was ve...ns could also trigger the "Mozart Effect." Patient...
...at Kansas State University have published the firs...educed by another compound in the egg, the lecith...Jiang and Sang K. Noh. A peer-reviewed research pa...choline decreses the lymphatic absorption of chole...
...(MSI), the sole franchisee for US based Medicine S...vi Mumbai, Baroda and Pune, has dropped Chennai fr...y. According to informed sources, MSI, which recen...ions from the present 19 outlets to 50 by the end ...
... levels may depend not only on what he or she eats...iddle-aged and older adults who ate frequently thr...vels compared with those who tended to down one or...act that the frequent eaters, on average, had a hi...
Other Medicine News:Health News:Lecithin lowers cholesterol absorption in body 2
(Date:9/3/2008)...alysis showed that Multaq(R) (dronedarone) decreas...l fibrillation or atrial flutter already ... BRIDGEWATER, N.J., Sept. 3 /PRNewswire-FirstCall/... from the ATHENA study were presented today at,the...iety of Cardiology,congress 2008, in Munich, Germa...
(Date:9/3/2008)...09 to be Evaluated in Repeat-Dosing Study in Subje...re-FirstCall/ -- Sangamo,BioSciences, Inc. (Nasdaq...se,2 clinical trial (SB-509-801) to evaluate its d...degenerative motor-neuron disease for which there,...mo,s drug, SB-509, is an injectable formulation of...
(Date:9/2/2008)...elegates Join World Vision, ONE to Build Hope and ...swire/ -- Delegates to the,Republican Party Conven...communities around the world including evacuees in...V and AIDS in developing countries: "We are here,t...nviting party delegates to do,something unconventi...
(Date:9/2/2008)...t of three ongoing randomized chemotherapy combina...atment of specific cancers -, ROCKVILLE, Md., Sep...es, Inc. (Nasdaq: HGSI ) today reported initial t...clinical trial of its TRAIL receptor antibody,HGS-...(Velcade) in patients,with advanced multiple myelo...
Breaking Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Senator Frist and Convention Delegates Support AIDS-Affected People Around the World, Raise Funds for Gustav Evacuees 2Senator Frist and Convention Delegates Support AIDS-Affected People Around the World, Raise Funds for Gustav Evacuees 3Senator Frist and Convention Delegates Support AIDS-Affected People Around the World, Raise Funds for Gustav Evacuees 4Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 2Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 3Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 4Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 5Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 6AWWA Urges Science Based Approach in Addressing Pharmaceutical Compounds in Water 16924 1AWWA Urges Science Based Approach in Addressing Pharmaceutical Compounds in Water 16924 2AWWA Urges Science Based Approach in Addressing Pharmaceutical Compounds in Water 16924 3Antioxidant users dont live longer analysis of studies concludes 2904 1Antioxidant users dont live longer analysis of studies concludes 2904 2Antioxidant users dont live longer analysis of studies concludes 2904 3Hereditary breast cancer a high cost to patient and health care provider alike 16918 1Hereditary breast cancer a high cost to patient and health care provider alike 16918 2Hereditary breast cancer a high cost to patient and health care provider alike 16918 3Senetek PLC Reports 2007 Financial Results 16915 1Senetek PLC Reports 2007 Financial Results 16915 2Senetek PLC Reports 2007 Financial Results 16915 3
...07. Giaconda Ltd (ASX: GIA) today,announced that t...ved the Company,s Investigational New Drug applica...aR to treat patients with,Crohn,s Disease infected...P). , ,The Company understands that its lead produ...d to the FDA for this indication. There,are no ant...
..., 2007 /PRNewswire-FirstCall/ --,Allos Therapeutic...,European Communities, with a favorable opinion of...e European Medicines Agency (EMEA),has granted or...olate PDX (pralatrexate) for the treatment of pati...ly 2006, the U.S. Food and,Drug Administration (FD...
Other Medicine Technology:FDA approves MyocondaR IND for MAP in Crohn's Disease 2FDA approves MyocondaR IND for MAP in Crohn's Disease 3FDA approves MyocondaR IND for MAP in Crohn's Disease 4Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 2Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 3Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 4
...iCharts, is a state-of-the-art electronic medical ...8. It is a proven, comprehensive electronic medica...are providers at the point of care and to be share...nternet. AmkaiCharts chronicles patient history, e...
...fice seamlessly integrates practice management and...nd clinical workflow. Instantly access registratio...eporting information for multiple practices, provi...tely improves productivity by simplifying office w...
The ReSeeVit Slit Lamp System is an easy-to-use digital video imaging system that captures anterior segment and retinal images for documentation, diagnosis and patient education. The package includes
...e is an important movement in our country to provi...ns. In fact, recent government regulations require...s device affords your wheelchair-bound patients ea...t without having to leave their wheelchair. , ,The...
Medicine Products: